STOK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ST

Mkt Cap

$1.56B

Volume

592.79K

Next Earnings

November 3rd

Loading chart

ST

STOKStoke Therapeutics, Inc. Common Stock

STOK

Pay with—

Available Balance0.00

ST

Mkt Cap

$1.56B

Volume

592.79K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

A Closer Look at 5 Analyst Recommendations For Stoke TherapeuticsRatings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 $22.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 $35.00 Sumant Kulkarni Canaccord Genuity Lowers Buy $20.00 $21.00 Joseph Stringer Needham Maintains Buy $22.00 $22.00 Joseph Stringer Needham Maintains Buy $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.comBenzinga · Jun 28, 2024

Analyst Expectations For Stoke Therapeutics's FutureStoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 62.75% from the previous average price target of $12.75. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Stoke Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 - Joseph Stringer Needham Maintains Buy $22.00 - Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stoke Therapeutics. This information ...Full story available on Benzinga.comBenzinga · May 6, 2024

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 6, 2024

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to DeclineAxsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · Apr 29, 2024

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to DeclineStoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · Apr 25, 2024

Assessing Stoke Therapeutics: Insights From 6 Financial Analysts6 analysts have expressed a variety of opinions on Stoke Therapeutics (NASDAQ:STOK) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D 0 0 0 0 0 1M Ago 3 1 1 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Stoke Therapeutics, presenting an average target of $20.33, a high estimate of $35.00, and a low estimate of $13.00. This upward trend is apparent, with the current average reflecting a 59.45% increase from the previous average price target of $12.75. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Stoke Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.comBenzinga · Apr 4, 2024

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The WatchlistStoke Therapeutics' stock soars as positive data shows potential for their lead drug candidate, STK-001, in treating Dravet syndrome. Read here for more details.Seeking Alpha · Apr 4, 2024

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study DataStoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.Zacks Investment Research · Mar 27, 2024

What's Going On With Stoke Therapeutics Stock Tuesday?Stoke Therapeutics Inc (NASDAQ:STOK) shares are rising in Tuesday’s after-hours session, riding a wave a momentum higher despite announcing a proposed public offering after the bell. What To Know: After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering. Stoke said it expects to use the net proceeds to fund ...Full story available on Benzinga.comBenzinga · Mar 26, 2024

Crude Oil Moves Lower; TD SYNNEX Earnings Top EstimatesU.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1 Leading and Lagging Sectors Consumer discretionary shares jumped by 0.6% on Monday. In trading on Monday, utilities shares fell by 1%. Top Headline TD SYNNEX Corporation (NYSE: SNX) reported better-than-expected first-quarter earnings. The company reported first quarter adjusted earnings per share of $2.99, beating the street view of $2.84. The company reported quarterly revenue of $13.975 billion, missing the analyst view of $14.357 billion. Equities Trading UP Stoke Therapeutics, Inc. (NASDAQ: STOK) shares shot up 72% to $11.19 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Shares of Mesoblast Ltd (NASDAQ: MESO) got a boost, surging 66% to $3.6420 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to ...Benzinga · Mar 26, 2024

to start trading

ST

STOKStoke Therapeutics, Inc. Common Stock

STOK

Pay with—

Available Balance0.00

Your PositionYou don't own any STOK yet.

Related Tickers

Earnings